TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04165083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-0482
Description: IV infusion
Study: NCT02762994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01306019

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector
Description: Transduced cell product administered intravenously over approximately 30 minutes by authorized licensed personnel consistent with NIH Clinical Center Department of Transfusion Medicine's standard operating procedures for cellular products.
Study: NCT00565513

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood test
Description: cord blood and maternal milk test
Study: NCT01995331

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide,cyclosporine A
Description: Drug,cyclophosphamide,cyclophosphamide (30 mg/kg/day) administered intravenously (IV) over 1 hr for 4 consecutive days Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years. The dose of CSA was adjusted to maintain trough drug concentration above 150 μg/L and peak drug concentration above 300 μg/L.~Drug, human granulocyte colony-stimulating factor (rhG-CSF), 5 μg/kg/day subcutaneously starting 24 hrs after the fourth dose of cyclophosphamide, and it was withdrawed when ANC was \>1×109/L.
Study: NCT02351635

Intervention type: OTHER
Intervention: fecal calprotectin level
Description: Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.

Intervention type: OTHER
Intervention: fecal calprotectin level
Description: Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.

Intervention type: OTHER
Intervention: fecal calprotectin level
Description: Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.

Intervention type: OTHER
Intervention: fecal calprotectin level
Description: Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.

Intervention type: OTHER
Intervention: fecal calprotectin level
Description: Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
Study: NCT03525340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigation
Description: Peer navigators help participants identify barriers that pose challenges to the participant's engagement in care and adherence and help develop an overall action plan for addressing these barriers by identifying specific changes that can be made/attempted to overcome an identified barrier. This may involve accompanying a participant to their social services/health appointments, or assisting a participant with disclosure of her HIV status to a family member or friend. The overall goal is to develop knowledge of social/HIV-related health services and good problem-solving skills in order to tackle multiple, potentially overlapping barriers. Over time, participants are encouraged to take increasing degrees of responsibility for identifying and implementing their own problem-solving strategies.
Study: NCT02232334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Osteopathic Manual Treatment
Description: subtle manipulations of the body according to the methodology of osteopathic manual therapy will be the intervention on subjects in the study. The global treatments will take into consideration the past medical history of each subject as well as what is found on assessment. Focus is on the position, mobililty and quality of each subjects anatomy.
Study: NCT01354327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Limicol
Description: 3 tablets / day during 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets / day during 4 months
Study: NCT03862950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Medication
Description: Placebo liquid or capsules given in parallel to active medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Active medication
Study: NCT01387867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised home based exercise
Description: Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
Study: NCT04466176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: 2 inhalations of Test and Reference product in each study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT03616132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System
Description: Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
Study: NCT03849807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: the intervention group will receive 4 weeks of chiropractic care along with usual care(Cognitive-Behavioral, psychosocial Therapy).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants in the group will receive usual health (Cognitive-Behavioral, psychosocial Therapy) care or wish to engage in during the course of the study as well as receiving a passive movement control intervention delivered by a chiropractor 3 times per week in the same hospital setting as the group receiving chiropractic care.
Study: NCT03499548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INSPiRe Programme
Description: Intensive CBT for suicide
Study: NCT03369470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App Dexterity
Description: App based dexterity training by means of Finger Zirkus (see for more details: www.fingers-in-motion.de)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Theraband
Description: Active control being five traditional hand strengthening (Thera-band) exercises, which we published in our previous RCT, being feasible and effective in improving dexterity (for more details see for Kamm et al. 2015).
Study: NCT03901547

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Communication Skills Training
Description: Education training in the serious illness communication guide (SICG) by Ariadne labs.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Communication Skills Training
Description: Education training in the serious illness communication guide (SICG) by Ariadne labs.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Profile feedback
Description: Providing participants their personal documentation rate of SICG in the electronic medical record

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Profile feedback
Description: Providing participants their personal documentation rate of SICG in the electronic medical record

Intervention type: OTHER
Group type: OTHER
Intervention: Maslach burnout inventory
Description: Maslach burnout inventory

Intervention type: OTHER
Group type: OTHER
Intervention: Emotion Regulation Skills Question (ERSQ)
Description: This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL). This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL).

Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interview
Description: Interviewer asked subjects are a series of questions based on interview guide. Current guide designed to assess subject perception of implementation of training in clinical encounters, most recent encounter with patient with serious illness, barriers to documentation and coaching by faculty on communication. Interviews will be recorded and expected duration is 20-40 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Priming
Description: Participants will be provided a list of 30 patients they have encountered before that 1) have at least one documented note and 2) have a high probability for having serious illness as determined by electronic medical record screening. Participants will be asked 4 yes or no questions on each patient. Questions: 1) do you believe this patient has serious illness?; 2) would you be surprised if this patient died in the next year?; 3) would the patient benefit from the serious illness conversation guide? and 4) If you saw this patient again, would you use the serious illness conversation guide with him/ her?
Study: NCT02841436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE) System
Study: NCT05099081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diode laser application
Description: Local anesthesia will be applied Lesion will be excised with diode laser (Medency, Italy) continuous wave mode 980 nm wave length with an output power 3 W in contact mode

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intra-lesional injection of ethanolamine oleate
Description: Local anesthesia will be applied Injection of ethanolamine oleate (sclerosing gent) with concentration 5% diluted in distilled water to form 2.5% ethanolamine oleate According to lesion size range from 1.5 to 3 ml of solution will be injected slowly into lesion using gauge needle until leaked from lesion.~Lesion will be compressed for 5 minutes. Lesion will be observed once a week after injection until it becomes necrotic and falls off spontaneously.~Repeated injection may be needed.
Study: NCT02848170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Description: CS-3150 2.5mg, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan medoxomil
Description: olmesartan medoxomil 10 mg, oral
Study: NCT00515177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eszopiclone
Description: One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of as needed use
Study: NCT01967342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Ed
Description: A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Pain
Description: A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
Study: NCT01975961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
Study: NCT03227133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluations
Description: Neuropsychological evaluations including oral fluency, performed specifically for the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk assessment
Study: NCT01975961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
Study: NCT00678327

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT02759809

Intervention type: OTHER
Intervention: Pasteurized donor human breastmilk

Intervention type: OTHER
Intervention: Preterm formula
Study: NCT03026777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous crystalloid fluid, 500 mL
Study: NCT00779610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vibration with flexion
Description: Vibration with forearm flexion (active contraction)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vibration without flexion
Description: Vibration without forearm flexion (passive)
Study: NCT03914833

Intervention type: OTHER
Intervention: Inclusion Questionnaires
Description: During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)

Intervention type: OTHER
Intervention: Inclusion Questionnaires
Description: During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)

Intervention type: OTHER
Intervention: Questionnaires at inclusion, M1 and M3
Description: During the inclusion visit, the 1-month visit and the 3-month visit; neuropsychologist grading of the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Index) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
Study: NCT04297735

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care group
Description: Visits every 6 months is standard of care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine group
Description: Conduct monthly telemedicine 'skype' visit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Review details of medication indication and use, activity recommendations and changes, and knowledge of arrhythmia changes and activities which are helpful with arrhythmia changes.
Study: NCT00500331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: Experimental Drug

Intervention type: DRUG
Group type: OTHER
Intervention: pioglitazone
Description: Active Control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT02117271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: device to treat obstructive sleep apnea using positive airway pressure with a nasal mask

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Breathe Right ®
Description: Nasal dilator strip treatment used during sleep to open the nasal airway
Study: NCT03823508

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal tDCS
Description: Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and a high density EEG. The anode will be placed over F3 in order to stimulate the left dorsolateral prefrontal cortex and the cathode over the right supraorbital area.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
Study: NCT06429111

Intervention type: PROCEDURE
Intervention: Epidural analgesia
Description: Consists of a central nerve block by injecting a local anesthetic near the nerves that transmit pain, in the lumbar region, for pain relief during labor.

Intervention type: PROCEDURE
Intervention: Immersion water
Description: Consists of the use of hot water immersion in a birthing tub during labor and/or delivery.
Study: NCT02575131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole wheat bread yeast basis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole wheat bread yeast basis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal
Study: NCT04502108

Intervention type: BEHAVIORAL
Intervention: Covid19
Description: Impact of the COVID19-pandemic on physical activity, nutritional habits and sleeping behavior during an extraordinary period of confinement and social distancing, during the loosening phase and social distancing and the phase after the pandemic.

Intervention type: BEHAVIORAL
Intervention: Covid19
Description: Impact of the COVID19-pandemic on physical activity, nutritional habits and sleeping behavior during an extraordinary period of confinement and social distancing, during the loosening phase and social distancing and the phase after the pandemic.
Study: NCT04336566

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin 5mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparable Good Neighbor Pharmacy placebo tablet
Study: NCT02264756

Intervention type: OTHER
Intervention: ASP review
Description: patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
Study: NCT02575131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cheerios

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cheerios

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole wheat sourdough bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole wheat sourdough bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard breakfast